Evidence map›Paper›PMID 32226703›Full record

ArticleApplied nanoscience2018

Effect of two glycyrrhizinic acid nanoparticle carriers on MARC-145 cells actin filaments.

Samantha Jardon, Carlos G García, David Quintanar, José L Nieto, María de Lourdes Juárez, Susana E Mendoza

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Applied nanoscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Samantha JardonUnidad de Investigación Multidisciplinaria L4 (Morfología Veterinaria y Biología Celular), UNAM-FESC, Campus 4, 54714 Cuautitlán Izcalli, Mexico.
Carlos G GarcíaUnidad de Investigación Multidisciplinaria L4 (Morfología Veterinaria y Biología Celular), UNAM-FESC, Campus 4, 54714 Cuautitlán Izcalli, Mexico.
David QuintanarLaboratorio de Investigación y Posgrado en Tecnología Farmacéutica, UNAM-FESC, Campus 1, 54714 Cuautitlán Izcalli, Mexico.
José L NietoUnidad de Investigación Multidisciplinaria L4 (Morfología Veterinaria y Biología Celular), UNAM-FESC, Campus 4, 54714 Cuautitlán Izcalli, Mexico.
María de Lourdes Juárez3Departamento de Morfología de la Facultad de Medicina Veterinaria y Zootecnia, UNAM-FMVZ, Mexico City, Mexico.
Susana E MendozaLaboratorio de Virología y Microbiología de las Enfermedades Respiratorias del Cerdo, UNAM-FESC, Campus 1, 54714 Cuautitlán Izcalli, Mexico.
Universidad de Cuautitlán Izcalli · MXUniversidad Nacional Autónoma de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of technologies that combine the advantages of nanomedicine with natural medicine represents a versatile approach to improve the safety and efficacy of drugs. Glycyrrhizinic acid (GA) is a natural compound that has a wide range of biological activities for the treatment of diseases. To establish a safe nanotransport system for this drug, two different nanoparticles with glycyrrhizinic acid, solid lipid nanoparticles (SLN-GA) and polymeric nanoparticles (PNP

Indexed as

Actin cytoskeletonCytotoxicityGlycyrrhizin acidMorphologic changesPolymeric nanoparticlesSolid lipid nanoparticles

Identifiers

PMID32226703
PMCPMC7096899
OpenAlexW2797288178

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.